Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00073827 · ClinicalTrials.gov registry record · Phase 3
Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 445
- Enrollment target
NCT00073827 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 445 participants.
The verdict
NCT00073827, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 445 participants
- Enrollment target
Study Summary
The primary purpose of this study was to investigate the efficacy of levalbuterol compared to a placebo and compared to albuterol in the treatment and prevention of bronchoconstriction in adolescent and adult subjects with asthma, with all treatments administered 4 times a day (QID).
Interventions
- DRUG Placebo
- DRUG racemic albuterol MDI
- DRUG levalbuterol tartrate MDI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 445 participants |
| Start Date | 2002-05 |
| Est. Completion | 2003-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00073827
The ClinicalTrials.gov registry entry for NCT00073827 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 445 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00073827 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00073827 about?
NCT00073827 is a clinical study titled "Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma". The primary purpose of this study was to investigate the efficacy of levalbuterol compared to a placebo and compared to albuterol in the treatment and prevention of bronchoconstriction in adolescent and adult subjects with asthma, with all treatments administered 4 times a day (QID).
What is the current status of trial NCT00073827?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 445 participants. The study started on 2002-05. Estimated completion is 2003-01.
What interventions are being tested in trial NCT00073827?
The interventions under investigation include: Placebo (DRUG), racemic albuterol MDI (DRUG), levalbuterol tartrate MDI (DRUG).
Who is sponsoring clinical trial NCT00073827?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.